arbaclofen-placarbil and Nausea

arbaclofen-placarbil has been researched along with Nausea* in 1 studies

Trials

1 trial(s) available for arbaclofen-placarbil and Nausea

ArticleYear
Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:8

    It has been shown that arbaclofen placarbil (AP) inhibits reflux in gastroesophageal reflux disease (GERD) following single oral dosing. This study evaluated the efficacy and safety of AP over 4 weeks in subjects with symptomatic GERD.. One hundred fifty-six subjects with heartburn and/or regurgitation ≥3 days/week and either no history of taking proton pump inhibitors (PPIs naive, n=58) or at least partial symptom response to PPI therapy (PPI responsive, n=98) were enrolled in this randomized, double-blind, placebo-controlled trial. All GERD therapies including PPIs were discontinued 2 weeks before randomization to AP 20, 40, or 60 mg daily, 30 mg twice daily, or placebo for 4 weeks. Randomization was stratified by prior PPI use.. In the primary analysis, change from baseline in weekly heartburn events between AP and placebo for the entire study group was not statistically significant. However, a significant interaction was observed between prior PPI use and response to AP treatment. In pre-planned secondary analyses of the PPI-responsive subgroup, percent reductions from baseline in weekly heartburn events were greater for each AP dose vs. placebo (P<0.05) and the percentage of subjects who reported complete resolution of heartburn during week 4 was higher in each AP treatment group (21, 28, 30, and 50% for AP 20, 40, 60 mg daily, and 30 mg twice daily, respectively) compared with placebo (6%) (P<0.05 for 30 mg twice daily). Corresponding analyses of the PPI-naive subgroup showed no significant differences. AP was well tolerated; withdrawals due to adverse events were infrequent.. AP was not superior to placebo in reducing the number of weekly heartburn events over 4 weeks in the primary analysis of the entire study population. Exploratory subgroup analyses suggest that response to PPI treatment before the study was associated with a response to AP treatment.

    Topics: Adult; Aged; Baclofen; Dizziness; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Gastroesophageal Reflux; Headache; Heartburn; Humans; Male; Middle Aged; Muscle Relaxants, Central; Nausea; Prodrugs; Proton Pump Inhibitors; Treatment Failure

2011